Company intelligence / Profile preview
Second Genome
Brisbane, California, United States
- Ownership
- Private
- Employees
- ~25
- Development stage
- Phase 1
01
Overview
Lead program SG-2-0776 is in pre-clinical and IND-enabling studies for inflammatory bowel disease. SG-5-00455 targets mucosal healing in IBD patients. SG-3-06686 is being developed as a CXCR3 immune activator for tumor growth inhibition.
- Therapeutic areas
- GastroenterologyOncologyImmunologyInfectious Diseases
- Modalities
- Proteinspeptidessmall molecules
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
Beyond the preview
Go deeper on Second Genome.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Second Genome.